Jefferies Group's PTCT Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 1.35 M shares of PTC Therapeutics, Inc. (PTCT) worth $92.28 M, representing 0.63% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 11 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in PTCT, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 1.58 M shares. Largest reduction occurred in Q4 2024, reducing 522,895 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's PTC Therapeutics (PTCT) Holding Value Over Time
Track share changes against reported price movement
Quarterly PTC Therapeutics (PTCT) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -304,022 | Reduce 18.33% | 1.35 M | $68.13 |
| Q4 2025 | +73,803 | Add 4.66% | 1.66 M | $75.96 |
| Q3 2025 | +1.58 M | New Buy | 1.58 M | $61.37 |
| Q4 2024 | -522,895 | Sold Out | 0 | $0.00 |
| Q2 2024 | +250,000 | Add 91.61% | 522,895 | $30.58 |
| Q1 2024 | -4,000 | Reduce 1.44% | 272,895 | $29.09 |
| Q4 2023 | +8,760 | Add 3.27% | 276,895 | $27.56 |
| Q3 2023 | +240 | Add 0.09% | 268,135 | $22.41 |
| Q2 2023 | +252,095 | Add 1595.54% | 267,895 | $40.67 |
| Q1 2023 | +15,800 | New Buy | 15,800 | $48.44 |
Jefferies Group's PTC Therapeutics Investment FAQs
Jefferies Group first purchased PTC Therapeutics, Inc. (PTCT) in Q1 2023, acquiring 15,800 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held PTC Therapeutics, Inc. (PTCT) for 11 quarters since Q1 2023.
Jefferies Group's largest addition to PTC Therapeutics, Inc. (PTCT) was in Q3 2025, adding 1,584,678 shares worth $97.25 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 1,354,459 shares of PTC Therapeutics, Inc. (PTCT), valued at approximately $92.28 M.
As of the Q1 2026 filing, PTC Therapeutics, Inc. (PTCT) represents approximately 0.63% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in PTC Therapeutics, Inc. (PTCT) was 1,658,481 shares, as reported at the end of Q4 2025.